Pemetrexed therapy — Competitive Intelligence Brief

Pemetrexed therapy (Pemetrexed therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimetabolite. Area: Oncology.

phase 3 Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase Oncology Small molecule

Target snapshot

Pemetrexed therapy (Pemetrexed therapy) — The First Affiliated Hospital with Nanjing Medical University. Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pemetrexed therapy TARGET	Pemetrexed therapy	The First Affiliated Hospital with Nanjing Medical University	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Intrathecal injection of pemetrexed	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed Disodium Heptahydrate	Pemetrexed Disodium Heptahydrate	ECOG-ACRIN Cancer Research Group	phase 3	Antimetabolite; multitargeted antifolate	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Bevacizumab and Pemetrexed/platinum	Bevacizumab and Pemetrexed/platinum	Sun Yat-sen University	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy	VEGF (bevacizumab); thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (platinum)
Pemetrexed plus Carboplatin or Cisplatin	Pemetrexed plus Carboplatin or Cisplatin	Avistone Biotechnology Co., Ltd.	phase 3	Antifolate antimetabolite combined with platinum-based chemotherapy	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed + Cisplatin /Carboplatin	Pemetrexed + Cisplatin /Carboplatin	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimetabolite class)

1. Allist Pharmaceuticals, Inc. · 1 drug in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
3. Mundipharma K.K. · 1 drug in this class
4. Radboud University Medical Center · 1 drug in this class
5. Shanghai Miracogen Inc. · 1 drug in this class
6. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
7. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class